A reliable model system that is relevant to the disease in question is a critical asset to achieve development of safe and effective therapeutics. It is in particular relevant for glioblastoma, since this tumor is composed of heterogeneous multiple types of tumor cells in patients. Recent studies identified that application of the spheroid cultures enables us to maintain the original phenotypic and genetic characteristics of the parental tumors. Core C will utilize its current services to collect additional glioblastoma spheroids (GSs) from affected patients and uncover the phenotypic and genotypic characteristics of these GSs are particularly relevant to each project as detailed in aim 2. Specifically, we will establish spheroid cultures from surgical specimens and perform in vivo tumorigenicity assay to determine if our samples are able to recapitulate patients'tumors histopathologically. We also would plan to provide these services on an ongoing basis for all five years of the grant since characterized GSs transferred to each project may require re-characterization. As such, this Core will provide services essential to all 4 projects. Significance of this Core as a central biorepository will eliminate variability amongst the projects, ensuring that all projects utilize the same GSs for the proposed experiments.

Public Health Relevance

Increasing bodies of evidence suggest that long-term cultures of tumor cells in serum-containing medium, including conventional cell lines, result in undesired phenotypic and genetic transformation of the original tumors. Our spheroid cultures from surgical specimens will create concrete path for the proposed projects to target the right kinds of tumor cells to evaluate therapeutics. Characterization of the samples with the proposed spheroid cultures will also deepen our understanding of the diseases in question.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Saini, Uksha; Naidu, Shan; ElNaggar, Adam C et al. (2017) Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene 36:168-181
Jaime-Ramirez, Alena Cristina; Dmitrieva, Nina; Yoo, Ji Young et al. (2017) Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide. J Gene Med 19:
Chen, L; Mao, H; Zhang, J et al. (2017) Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Leukemia 31:1830-1834
Choudhury, Sourav R; Hudry, Eloise; Maguire, Casey A et al. (2017) Viral vectors for therapy of neurologic diseases. Neuropharmacology 120:63-80
Freud, Aharon G; Mundy-Bosse, Bethany L; Yu, Jianhua et al. (2017) The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity 47:820-833
Lee, Tae Jin; Yoo, Ji Young; Shu, Dan et al. (2017) RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21. Mol Ther 25:1544-1555
Jaime-Ramirez, Alena C; Yu, Jun-Ge; Caserta, Enrico et al. (2017) Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma. Mol Ther Oncolytics 5:87-96
Huang, Tianzhi; Kim, Chung Kwon; Alvarez, Angel A et al. (2017) MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma. Cancer Cell 32:840-855.e8
Bolyard, Chelsea; Meisen, W Hans; Banasavadi-Siddegowda, Yeshavanth et al. (2017) BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy. Clin Cancer Res 23:1809-1819
Dai, Hong-Sheng; Griffin, Nathaniel; Bolyard, Chelsea et al. (2017) The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. Immunity 47:159-170.e10

Showing the most recent 10 out of 107 publications